Baxter Advate
This article was originally published in The Gray Sheet
Executive Summary
Hemophilia A therapy gains FDA sign-off July 25. Shipments of the recombinant antihemophilic factor plasma/albumin-free method (rAHF-PFM) product to distributors will begin in three to six weeks. Baxter has projected that the product will help drive BioScience unit growth of 5%-10% this year (1"The Gray Sheet" July 21, 2003, p. 13)...